Figure 1
Figure 1. Inhibitory activity of STA-5326 on IL-12 p70, IL-23, and total p40 in human PBMCs. Human PBMCs were primed with IFN-γ and then stimulated with SAC in the presence of different concentrations of STA-5326. Supernatants were tested for IL-12 p70 (⋄), IL-23 (□), and total p40 (▵), and the levels in compound-free control were 15 pg/mL, 1.2 ng/mL, and 5.5 ng/mL, respectively. Results are shown as mean percentage of inhibition of 1 representative of 3 individual experiments. Compared with the level of corresponding compound-free control, P < .001 at concentrations 8 to 1000 nM, 8 to 1000 nM, and 1.6 to 1000 nM of STA-5326 for IL-12 p70, IL-23, and total p40, respectively.

Inhibitory activity of STA-5326 on IL-12 p70, IL-23, and total p40 in human PBMCs. Human PBMCs were primed with IFN-γ and then stimulated with SAC in the presence of different concentrations of STA-5326. Supernatants were tested for IL-12 p70 (⋄), IL-23 (□), and total p40 (▵), and the levels in compound-free control were 15 pg/mL, 1.2 ng/mL, and 5.5 ng/mL, respectively. Results are shown as mean percentage of inhibition of 1 representative of 3 individual experiments. Compared with the level of corresponding compound-free control, P < .001 at concentrations 8 to 1000 nM, 8 to 1000 nM, and 1.6 to 1000 nM of STA-5326 for IL-12 p70, IL-23, and total p40, respectively.

Close Modal

or Create an Account

Close Modal
Close Modal